Who
Robert J. Spiegel
Director
Company insider
Files Form 4 as: Director, RenovoRx; Director, Geron; Director, Bio Green Med Solution; Director, Athenex; Director, Old Ayala; Director, Ayala Pharmaceuticals; Director, PDS Biotechnology; Director, Sucampo Pharmaceuticals.
In numbers
- Trades disclosed
- 179
- Buys
- 2
- Sells
- 3
- Bought
- $33K
- Sold
- $1.3M
- Companies
- 11
- Companies where not an officer
- 10
- First trade
- 21 May 2010
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,924 at $0.00 | filing |
| 30 Sep 2026filed 1 Oct 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8126,351 at $1.23 | filing |
| 30 Jun 2026filed 1 Jul 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8126,103 at $1.28 | filing |
| 30 Jun 2026filed 1 Jul 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8126,103 at $1.28 | filing |
| 20 May 2026filed 26 May 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 20 May 2026filed 26 May 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8125,243 at $1.49 | filing |
| 31 Mar 2026filed 1 Apr 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8125,243 at $1.49 | filing |
| 31 Dec 2025filed 5 Jan 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8125,918 at $1.32 | filing |
| 31 Dec 2025filed 5 Jan 2026 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8125,918 at $1.32 | filing |
| 1 Oct 2025filed 2 Oct 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,640 at $0.00 | filing |
| 30 Sep 2025filed 1 Oct 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8125,702 at $1.37 | filing |
| 30 Jun 2025filed 1 Jul 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8115,540 at $1.41 | filing |
| 21 May 2025filed 22 May 2025 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8124,913 at $1.59 | filing |
| 31 Dec 2024filed 2 Apr 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | $7,8092,206 at $3.54 | filing |
| 31 Dec 2024filed 2 Jan 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | —2,206 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,099 at $0.00 | filing |
| 30 Sep 2024filed 2 Apr 2025 | GERN GeronBiotechnology | SEC FORM 4 Code A | $8,0221,767 at $4.54 | filing |
| 30 Sep 2024filed 1 Oct 2024 | GERN GeronBiotechnology | SEC FORM 4 Code A | —1,767 at $0.00 | filing |
News
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinicmanilatimes.net · 1 Oct 2026Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)GERN · tickerreport.com · 20 Oct 2026PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastPTCT · dailypolitical.com · 19 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Director Michael Schmertzler Sells 2,500 Shares of Company StockPTCT · tickerreport.com · 16 Oct 2026PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 SharesPTCT · themarketsdaily.com · 9 Oct 2026
1 headline in the last 90 days name Robert J. Spiegel; 4 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.